NeoGenomics（NEO）株式概要
ネオジェノミクス社は、米国と英国でがんに特化した検査施設のネットワークを運営している。 詳細
NEO Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
NeoGenomics, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$19.91 |
| 52週高値 | US$20.03 |
| 52週安値 | US$7.07 |
| ベータ | 1.75 |
| 1ヶ月の変化 | 17.26% |
| 3ヶ月変化 | 73.58% |
| 1年変化 | 137.02% |
| 3年間の変化 | 61.08% |
| 5年間の変化 | -57.58% |
| IPOからの変化 | 665.77% |
最新ニュース
ナラティブ更新 • Sep 03
NEO: Expanded Coverage And Legal Win Will Support But Limit Future Upside
Analysts have raised their fair value price target for NeoGenomics from $11.00 to $16.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for NeoGenomics NeoGenomics received expanded MolDX Medicare coverage for its RaDaR ST molecular residual disease assay, now including immunotherapy monitoring for patients with late stage solid tumors.
ナラティブ更新 • Aug 19
NEO: Companion Diagnostics Expansion Will Drive Long Term Upside
Analysts have raised their price target on NeoGenomics from about $23.01 to roughly $31.05, citing updated assumptions about the company’s discount rate, revenue growth, profit margin and future P/E profile. What’s in the News for NeoGenomics NeoGenomics issued revised earnings guidance for the full year 2026, with expected consolidated revenue of US$802 million to US$806 million, an expected net loss of US$42 million to US$34 million, and an expected GAAP net loss per diluted share of US$0.32 to US$0.26.Recent updates
ナラティブ更新 • Sep 03
NEO: Expanded Coverage And Legal Win Will Support But Limit Future Upside
Analysts have raised their fair value price target for NeoGenomics from $11.00 to $16.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for NeoGenomics NeoGenomics received expanded MolDX Medicare coverage for its RaDaR ST molecular residual disease assay, now including immunotherapy monitoring for patients with late stage solid tumors.ナラティブ更新 • Aug 19
NEO: Companion Diagnostics Expansion Will Drive Long Term Upside
Analysts have raised their price target on NeoGenomics from about $23.01 to roughly $31.05, citing updated assumptions about the company’s discount rate, revenue growth, profit margin and future P/E profile. What’s in the News for NeoGenomics NeoGenomics issued revised earnings guidance for the full year 2026, with expected consolidated revenue of US$802 million to US$806 million, an expected net loss of US$42 million to US$34 million, and an expected GAAP net loss per diluted share of US$0.32 to US$0.26.
ナラティブ更新 • Aug 05
NEO: New Prostate Diagnostic Will Support Future Repricing
Analysts have lifted their price target on NeoGenomics from about $16.22 to roughly $19.72, citing updated fair value estimates and expectations for a higher future P/E multiple, while keeping revenue growth and profit margin assumptions broadly similar. What’s in the News for NeoGenomics NeoGenomics updated full year 2026 guidance and now expects consolidated revenue of US$802 million to US$806 million, compared with prior guidance of US$797 million to US$803 million.ナラティブ更新 • Jul 22
NEO: New Prostate Diagnostic And Compliance Resolution Will Support Future Repricing
Analysts have modestly raised their price target on NeoGenomics to $16.22 from $15.06, citing updated assumptions for fair value, profit margin, and future P/E that support a slightly higher valuation framework. What’s in the News for NeoGenomics NeoGenomics launched PTEN IHC CDx, described as the first FDA approved immunohistochemistry companion diagnostic test for prostate adenocarcinoma, to identify PTEN protein loss in patients who may be eligible for AstraZeneca’s TRUQAP (capivasertib).ナラティブ更新 • Jul 08
NEO: Strong Testing Momentum Will Be Tempered By Rich Earnings Multiple
Analysts have adjusted their price target for NeoGenomics from $13.00 to $11.00. They cite updated assumptions on the discount rate, revenue growth, profit margin, and future P/E ratio, which they believe more accurately reflect the stock's risk and return profile.ナラティブ更新 • Jun 24
NEO: Debt Refinancing And Buybacks Will Support Long Term Upside
Analysts have trimmed their price target on NeoGenomics to about $23.01 from roughly $23.43 as they factor in updated assumptions around discount rates, revenue growth, profit margins, and a much higher future P/E. Taken together, these changes point to a slightly lower fair value estimate for the stock.分析記事 • Jun 17
NeoGenomics (NEO) Stock Could Be 30.3% Undervalued on Its PanTracer Growth Narrative
NeoGenomics (NEO) is back on investor radars after recent trading showed sharp short term swings, with the stock down over the past week but up strongly over the past month and past 3 months. See our latest analysis for NeoGenomics. Looking past the latest pullback, NeoGenomics has a 1 year total shareholder return of 50.07% despite a year to date share price decline of 10.80%. This suggests recent momentum has cooled after a strong rebound over the past quarter. If the recent swings in...ナラティブ更新 • Jun 09
NEO: Expanded Epic Access And Medicare Coverage Will Drive Future Repricing
Analysts have adjusted their price target on NeoGenomics to $15.06. The update reflects tweaks to assumptions around the discount rate, long term profit margin and future P/E, while leaving the implied fair value estimate unchanged.ナラティブ更新 • May 26
NEO: Expanded Test Access And Medicare Coverage Will Support Future Repricing
Analysts have raised their price target on NeoGenomics to $15.06, up from $14.19, citing updated assumptions around discount rates, profit margins, and future P/E expectations. What's in the News Updated full year 2026 revenue guidance to a range of US$797 million to US$803 million, compared with prior guidance of US$793 million to US$801 million, while maintaining an expected net loss of US$63 million to US$50 million and net loss per diluted share of US$0.48 to US$0.38 (Corporate guidance) Oncology testing portfolio made available through Epic Aura, allowing oncologists and health systems across the United States to order tests and view results directly within Epic electronic health records.ナラティブ更新 • May 01
NEO: Expanded Test Access And Coverage Will Support Long Term Upside
Analysts have revised their fair value estimate for NeoGenomics from $17.00 to about $23.43. This change reflects updated assumptions for long term revenue growth, profit margins, and a higher future P/E multiple.ナラティブ更新 • Apr 17
NEO: Medicare Test Coverage Will Support Bullish Repricing Through 2026 Guidance
Analysts have trimmed their price target on NeoGenomics from about $14.81 to roughly $14.19, citing updated assumptions for fair value, revenue growth, profit margin and future P/E that modestly reset expectations while keeping the broader thesis intact. What's in the News PanTracer LBx received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043.ナラティブ更新 • Apr 03
NEO: Expanded Genomic Test Coverage Will Support Stronger Outlook For 2026
Analysts have raised their price target on NeoGenomics from $12.00 to $13.00, citing updated assumptions for growth, profitability, discount rate, and a higher future P/E multiple. What's in the News PanTracer LBx liquid biopsy test received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043, expanding access for Medicare patients to blood based comprehensive genomic profiling across more than 500 genes with a seven day turnaround (Key Developments).ナラティブ更新 • Mar 19
NEO: New Medicare Coverage Will Drive Bullish Repricing Through 2026 Guidance
Analysts have kept their $14.81 price target for NeoGenomics unchanged, citing stable modeled revenue growth, profit margins, and future P/E assumptions as the basis for maintaining their view. What's in the News Medicare, through the MolDX program, granted coverage for NeoGenomics' PanTracer LBx liquid biopsy test for plasma based genomic profiling in solid tumors, expanding access for Medicare patients to a blood based comprehensive genomic profiling assay that evaluates more than 500 genes with a seven day turnaround (Key Developments).ナラティブ更新 • Mar 05
NEO: Legal Victory And 2025–2026 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on NeoGenomics from about $14.43 to roughly $14.81, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News NeoGenomics launched RaDaR ST, a circulating tumor DNA assay for molecular residual disease that uses patient specific, tumor informed panels and whole exome sequencing to track up to 48 tumor variants with an LOD95 of 11 ppm.ナラティブ更新 • Feb 19
NEO: Liquid Biopsy Expansion And Legal Win Will Support Long Term Upside
Analysts have kept their $17.00 price target for NeoGenomics unchanged, reflecting only small model tweaks to the discount rate, revenue growth assumptions, profit margin expectations, and future P/E that do not materially alter their overall view of the stock. What's in the News Issued earnings guidance for 2026 with expected consolidated revenue of US$793 million to US$801 million and a projected net loss of US$63 million to US$50 million.ナラティブ更新 • Feb 05
NEO: Fair Outlook Balances Leadership Transition Patent Win And Clinical Data
Narrative Update on NeoGenomics Analysts have lifted their implied fair value estimate for NeoGenomics to US$12.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E as the key drivers behind the new price target framework. What’s in the News NeoGenomics announced a CFO succession plan, with Abhishek Jain joining as Executive Vice President on January 12, 2026 and scheduled to become CFO on March 2, 2026, as current CFO Jeff Sherman transitions toward retirement on April 14, 2026, after completing the fiscal 2025 reporting cycle.Seeking Alpha • Jan 25
NeoGenomics: Distribution Moat In Community Oncology
Summary NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO’s clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration. NEO trades at a significant discount to sector peers on EV/Sales and P/S, offering a margin of safety if execution on MRD and margin expansion materializes. Read the full article on Seeking Alphaナラティブ更新 • Jan 22
NEO: Legal Win And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target for NeoGenomics to about US$14.43 from roughly US$13.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that refine their view of the company’s long-term earnings power. What's in the News Issued preliminary unaudited guidance for the fourth quarter of 2025 with expected total revenue of about US$190 million and year over year growth of 11%, and full year 2025 revenue of about US$727 million with year over year growth of 10% (company guidance).ナラティブ更新 • Jan 08
NEO: Future Liquid Biopsy Data Pipeline Will Support Stronger Long Term Outlook
Analysts have lifted their fair value estimate for NeoGenomics from US$14.00 to US$17.00. They cite updated assumptions around revenue growth, profit margins and future P/E that they believe better reflect the company’s outlook.ナラティブ更新 • Dec 14
NEO: Upcoming Trial Readouts And Guidance Will Drive Bullish Repricing
Narrative Update on NeoGenomics Analysts have modestly raised their price target on NeoGenomics to approximately 13.44 dollars from about 13.17 dollars, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite a nearly unchanged discount rate and profit margin outlook. What's in the News Upcoming SABCS 2025 presentations will showcase RaDaR 1.0 ctDNA data from the SURVIVE HERoes Phase III trial and CLEVER study in early breast cancer, supporting ctDNA guided surveillance and earlier intervention strategies (company announcement).ナラティブ更新 • Nov 29
NEO: Upcoming Research and Earnings Guidance Will Shape Market Expectations
Analysts have slightly raised their price target for NeoGenomics from $13.06 to $13.17 per share. This reflects updated assessments of future profitability and market growth potential.ナラティブ更新 • Nov 15
NEO: Upcoming Research Presentations Are Expected To Drive Solid Tumor Detection Momentum
Analysts have raised their fair value estimate for NeoGenomics from $11.72 to $13.06. This change is attributed to slightly improved revenue growth projections, as well as a modest increase in profit margins and future valuation multiples.ナラティブ更新 • Nov 01
NEO: Upcoming Research Presentations Will Accelerate Future Oncology Diagnostic Opportunities
Analysts have raised their price target for NeoGenomics from $10.44 to $11.72 per share. They cite marginal improvements in projected revenue growth and profit margin estimates.ナラティブ更新 • Oct 18
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
Analysts have raised their price target for NeoGenomics from $9.78 to $10.44 per share, citing slightly improved revenue growth projections and a modestly higher future price-to-earnings multiple. What's in the News NeoGenomics announced the presentation of key MRD assay data, including results from interventional therapy trials, at the upcoming ESMO Congress 2025 in Berlin.ナラティブ更新 • Aug 30
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
The higher analyst price target for NeoGenomics reflects an expansion in its future P/E multiple despite stable revenue growth forecasts, resulting in a revised fair value of $9.78. What's in the News U.S. District Court invalidated certain Natera patents asserted against NeoGenomics’ RaDaR v1.1 test, but the decision does not affect the '035 patent that previously led to a permanent injunction on RaDaR v1.0. NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test targeting the expanding liquid biopsy market and enhancing its pan-solid tumor CGP portfolio.分析記事 • Aug 27
Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jul 30
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • May 23
Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 25% in the last thirty...
新しいナラティブ • Mar 23
PanTracer Launch And MRD Collaboration Will Strengthen Future Cancer Testing Leadership
NeoGenomics' strategic investments and collaborations are expected to enhance customer experiences, boost test volumes, and strengthen competitive positioning in MRD monitoring and Heme testing.分析記事 • Mar 08
NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 28% in the last thirty...Seeking Alpha • Feb 28
NeoGenomics: Decent Fundamentals, But Still Overvalued
Summary NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitability is a concern. Intrinsic value calculations using the Graham's Formula and DCF model suggest the stock may not yet be done falling. I am recommending caution. Read the full article on Seeking Alpha株主還元
| NEO | US Healthcare | US 市場 | |
|---|---|---|---|
| 7D | 8.1% | -3.0% | -0.1% |
| 1Y | 137.0% | 15.8% | 11.9% |
業界別リターン: NEO過去 1 年間で15.8 % の収益を上げたUS Healthcare業界を上回りました。
リターン対市場: NEO過去 1 年間で11.9 % の収益を上げたUS市場を上回りました。
価格変動
| NEO volatility | |
|---|---|
| NEO Average Weekly Movement | 8.1% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: NEO 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: NEOの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2001 | 2,500 | Tony Zook | www.neogenomics.com |
ネオジェノミクス社は、米国と英国で癌に特化した検査ラボのネットワークを運営している。同社は病院、学術センター、病理医、腫瘍医、臨床医、製薬会社、臨床検査室に検査サービスを提供している。また、正常染色体および異常染色体と疾患との関係を調べる細胞遺伝学検査サービス、染色体上の特定のDNA配列および遺伝子の有無の検出と同定に焦点を当てた蛍光in-situハイブリダイゼーション検査サービス、細胞集団の特徴を測定するフローサイトメトリー検査サービス、組織切片中の細胞タンパク質の局在を調べる免疫組織化学およびデジタルイメージング検査サービス、スキャンしたスライドを可視化し、様々な染色の定量分析を行うことができるサービスも提供している。さらに、DNAやRNA、遺伝子の構造や機能を分子レベルで解析する分子検査サービス、病理医が診断のために顕微鏡下で細胞を分析する形態学的解析、創薬や商業化を目指す製薬企業のがんプログラムをサポートする検査サービスも提供している。同社は2001年に設立され、フロリダ州フォートマイヤーズに本社を置いている。
NeoGenomics, Inc. 基礎のまとめ
| NEO 基礎統計学 | |
|---|---|
| 時価総額 | US$2.56b |
| 収益（TTM） | -US$51.88m |
| 売上高(TTM) | US$766.30m |
3.3x
P/Sレシオ-49.3x
PER（株価収益率NEO は割高か？
公正価値と評価分析を参照収益と収入
| NEO 損益計算書（TTM） | |
|---|---|
| 収益 | US$766.30m |
| 売上原価 | US$429.76m |
| 売上総利益 | US$336.53m |
| その他の費用 | US$388.41m |
| 収益 | -US$51.88m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.40 |
| グロス・マージン | 43.92% |
| 純利益率 | -6.77% |
| 有利子負債／自己資本比率 | 47.6% |
NEO の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/21 11:15 |
| 終値 | 2026/09/18 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
NeoGenomics, Inc. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26
| アナリスト | 機関 |
|---|---|
| Michael Ryskin | BofA Global Research |
| Lu Li | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |